O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+11.03%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.48B
AUM Growth
+$5.48B
(+8.5%)
Cap. Flow
+$63.8M
Cap. Flow
% of AUM
1.16%
Top 10 Holdings %
Top 10 Hldgs %
32.95%
Holding
132
New
15
Increased
25
Reduced
27
Closed
11
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$111M |
| 2 |
United Therapeutics
UTHR
|
$88.7M |
| 3 |
Baxter International
BAX
|
$82.6M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$74.3M |
| 5 |
Cigna
CI
|
$45.2M |
Top Sells
| 1 |
Verastem
VSTM
|
$111M |
| 2 |
Bristol-Myers Squibb
BMY
|
$54.5M |
| 3 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$47M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$36.8M |
| 5 |
Progyny
PGNY
|
$33.3M |
Sector Composition
| 1 | Healthcare | 97.46% |
| 2 | Industrials | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $340M | 6.16% | 2,718,735 | – | – |
|
2
Intuitive Surgical
ISRG
$170B
| $212M | 3.84% | 620,500 | – | – |
|
3
Enliven Therapeutics
ELVN
$1.2B
| $184M | 3.33% | 8,998,338 +2,125 | +0% | +$43.4K |
|
4
Boston Scientific
BSX
$156B
| $183M | 3.31% | 3,379,900 -410,100 | -11% | -$22.2M |
|
|
THRX
5
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $161M | 2.91% | 17,233,668 | – | – |
|
6
Biogen
BIIB
$19.4B
| $159M | 2.87% | 556,800 +51,800 | +10% | +$14.8M |
|
7
Humana
HUM
$36.5B
| $156M | 2.83% | 348,700 | – | – |
|
|
8
Baxter International
BAX
$12.7B
| $154M | 2.79% | 3,375,000 +1,813,000 | +116% | +$82.6M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $140M | 2.54% | 1,615,210 | – | – |
|
10
UnitedHealth
UNH
$281B
| $117M | 2.13% | 244,000 -32,000 | -12% | -$15.4M |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $113M | 2.05% | 14,567,176 | – | – |
|
|
SLRN
12
DELISTED
ACELYRIN
SLRN
| $111M | 2.02% | +5,326,302 | New | +$111M |
|
|
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
| $110M | 1.99% | 4,178,588 -320,312 | -7% | -$8.4M |
|
14
Disc Medicine
IRON
$2.07B
| $101M | 1.83% | 2,269,637 | – | – |
|
|
15
Bristol-Myers Squibb
BMY
$96B
| $95.2M | 1.72% | 1,488,000 -852,000 | -36% | -$54.5M |
|
16
Ionis Pharmaceuticals
IONS
$6.79B
| $89M | 1.61% | 2,169,500 +45,000 | +2% | +$1.85M |
|
|
17
United Therapeutics
UTHR
$13.8B
| $88.7M | 1.61% | +401,900 | New | +$88.7M |
|
18
Evolent Health
EVH
$1.12B
| $87.7M | 1.59% | 2,895,632 | – | – |
|
|
VECT
19
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $87.7M | 1.59% | 5,156,561 | – | – |
|
20
Eli Lilly
LLY
$657B
| $87.2M | 1.58% | 186,000 | – | – |
|
21
Thermo Fisher Scientific
TMO
$186B
| $84.9M | 1.54% | 162,800 +15,000 | +10% | +$7.83M |
|
22
Apellis Pharmaceuticals
APLS
$3.48B
| $82.9M | 1.5% | 910,200 | – | – |
|
23
Stryker
SYK
$150B
| $82.8M | 1.5% | 271,400 -96,200 | -26% | -$29.3M |
|
|
VRNA
24
Verona Pharma
VRNA
$9.16B
| $79.9M | 1.45% | 3,777,778 -482,913 | -11% | -$10.2M |
|
25
Tenet Healthcare
THC
$16.3B
| $78.2M | 1.42% | 960,500 -259,800 | -21% | -$21.1M |
|